Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Operating Expenses for 16 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 53.12% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.6 million, a 13.86% decrease, with the full-year FY2025 number at $8.1 million, down 23.42% from a year prior.
  • Operating Expenses was $3.0 million for Q3 2025 at IGC Pharma, up from $2.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.5 million in Q1 2022 to a low of $1.6 million in Q1 2025.
  • A 5-year average of $2.8 million and a median of $2.6 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 157.7% in 2021, then plummeted 42.97% in 2024.
  • IGC Pharma's Operating Expenses stood at $2.4 million in 2021, then decreased by 2.74% to $2.4 million in 2022, then soared by 31.55% to $3.1 million in 2023, then plummeted by 36.7% to $2.0 million in 2024, then surged by 51.26% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Expenses are $3.0 million (Q3 2025), $2.1 million (Q2 2025), and $1.6 million (Q1 2025).